{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:49:13Z","timestamp":1783943353398,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","brainanddevelopment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.braindev.2017.03.029","type":"journal-article","created":{"date-parts":[[2017,4,22]],"date-time":"2017-04-22T02:00:34Z","timestamp":1492826434000},"page":"656-664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["The effect of dietary supplements on clinical aspects of autism spectrum disorder: A systematic review of the literature"],"prefix":"10.1016","volume":"39","author":[{"given":"Maria","family":"Gogou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kolios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2017.03.029_b0005","doi-asserted-by":"crossref","first-page":"739","DOI":"10.4088\/JCP.13ac08550","article-title":"Changes in the diagnostic criteria for autism in DSM-5: controversies and concerns","volume":"74","author":"Hazen","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.braindev.2017.03.029_b0010","first-page":"1","article-title":"Prevalence of autism spectrum disorder among children aged 8years \u2013 autism and developmental disabilities monitoring network, 11 sites, United States, 2010","volume":"63","author":"Centers for Disease Control and Prevention (CDC)","year":"2014","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.braindev.2017.03.029_b0015","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1007\/s10803-015-2521-7","article-title":"Brief report: Forecasting the economic burden of autism in 2015 and 2025 in the United States","volume":"45","author":"Leigh","year":"2015","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.braindev.2017.03.029_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5607\/en.2016.25.1.1","article-title":"A short review on the current understanding of autism spectrum disorders","volume":"25","author":"Park","year":"2016","journal-title":"Exp Neurobiol"},{"key":"10.1016\/j.braindev.2017.03.029_b0025","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.dld.2015.11.026","article-title":"Gastrointestinal symptoms and behavioral problems in preschoolers with autism spectrum disorder","volume":"48","author":"Fulceri","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.braindev.2017.03.029_b0030","article-title":"Unexpected improvement in core autism spectrum disorder symptoms after long-term treatment with probiotics","volume":"4","author":"Grossi","year":"2016","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.braindev.2017.03.029_b0035","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1542\/peds.2014-2121","article-title":"Core symptoms of autism improved after vitamin D supplementation","volume":"135","author":"Jia","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.braindev.2017.03.029_b0040","unstructured":"Neurology. The official journal of the American Academy of Neurology. http:\/\/www.neurology.org\/site\/misc\/NeurologyFiller.pdf (Accessed December 8, 2016)."},{"key":"10.1016\/j.braindev.2017.03.029_b0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13229-016-0088-6","article-title":"A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder","volume":"7","author":"Wink","year":"2016","journal-title":"Mol Autism"},{"key":"10.1016\/j.braindev.2017.03.029_b0050","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13229-015-0062-8","article-title":"A randomized, placebo-controlled trial of d-cycloserine for the enhancement of social skills training in autism spectrum disorders","volume":"7","author":"Minshawi","year":"2016","journal-title":"Mol Autism"},{"key":"10.1016\/j.braindev.2017.03.029_b0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/WNF.0000000000000063","article-title":"N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: A randomized, double-blind, placebo-controlled clinical trial of efficacy and safety","volume":"38","author":"Nikoo","year":"2015","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.braindev.2017.03.029_b0060","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/1471-244X-13-196","article-title":"A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders","volume":"13","author":"Ghanizadeh","year":"2013","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.braindev.2017.03.029_b0065","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.biopsych.2012.01.014","article-title":"A randomized controlled pilot trial of oral N-acetylcysteine in children with autism","volume":"71","author":"Hardan","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.braindev.2017.03.029_b0070","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1176\/appi.ajp.161.11.2115","article-title":"A pilot study of d-cycloserine in subjects with autistic disorder","volume":"161","author":"Posey","year":"2004","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.braindev.2017.03.029_b0075","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/088307380101600303","article-title":"Effectiveness of N,N-dimethylglycine in autism and pervasive developmental disorder","volume":"16","author":"Kern","year":"2001","journal-title":"J Child Neurol"},{"key":"10.1016\/j.braindev.2017.03.029_b0080","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaac.2014.01.018","article-title":"Internet-based, randomized controlled trial of omega-3 fatty acids for hyperactivity in autism","volume":"53","author":"Bent","year":"2014","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.braindev.2017.03.029_b0085","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPG.0000000000000260","article-title":"Dietary docosahexaenoic acid supplementation in children with autism","volume":"58","author":"Voigt","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.braindev.2017.03.029_b0090","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10803-010-1078-8","article-title":"A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder","volume":"41","author":"Bent","year":"2011","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.braindev.2017.03.029_b0095","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.biopsych.2006.05.007","article-title":"Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study","volume":"61","author":"Amminger","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.braindev.2017.03.029_b0100","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1089\/acm.2009.0177","article-title":"Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism","volume":"16","author":"Bertoglio","year":"2010","journal-title":"J Altern Complement Med"},{"key":"10.1016\/j.braindev.2017.03.029_b0105","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1023\/A:1025861522935","article-title":"High-dose pyridoxine and magnesium administration in children with autistic disorder: An absence of salutary effects in a double-blind, placebo-controlled study","volume":"27","author":"Findling","year":"1997","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.braindev.2017.03.029_b0110","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF01273191","article-title":"Inositol treatment of autism","volume":"104","author":"Levine","year":"1997","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.braindev.2017.03.029_b0115","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF01066428","article-title":"Brief Report: Lack of response in an autistic population to a low dose clinical trial of pyridoxine plus magnesium","volume":"23","author":"Tolbert","year":"1993","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.braindev.2017.03.029_b0120","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/0278-5846(93)90058-Z","article-title":"A preliminary trial of ascorbic acid as supplemental therapy for autism","volume":"17","author":"Dolske","year":"1993","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.braindev.2017.03.029_b0125","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0006-3223(85)90019-8","article-title":"Vitamin B6, magnesium, and combined B6-Mg: therapeutic effects in childhood autism","volume":"20","author":"Martineau","year":"1985","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.braindev.2017.03.029_b0130","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/pr.2013.248","article-title":"Effect of camel milk on thymus and activation-regulated chemokine in autistic children: double-blind study","volume":"75","author":"Bashir","year":"2014","journal-title":"Pediatr Res"},{"key":"10.1016\/j.braindev.2017.03.029_b0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/cap.2012.0048","article-title":"Long-term administration of intranasal oxytocin is a safe and promising therapy for early adolescent boys with autism spectrum disorders","volume":"23","author":"Tachibana","year":"2013","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.braindev.2017.03.029_b0140","doi-asserted-by":"crossref","first-page":"PI15","DOI":"10.12659\/MSM.881792","article-title":"A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders","volume":"17","author":"Geier","year":"2011","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.braindev.2017.03.029_b0145","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s10803-010-0974-2","article-title":"Digestive enzyme supplementation for autism spectrum disorders: a double-blind randomized controlled trial","volume":"40","author":"Munasinghe","year":"2010","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.braindev.2017.03.029_b0150","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3109\/19390210903280231","article-title":"First preliminary results of an observation of Panax ginseng treatment in patients with autistic disorder","volume":"6","author":"Niederhofer","year":"2009","journal-title":"J Diet Suppl"},{"key":"10.1016\/j.braindev.2017.03.029_b0155","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/BF01538042","article-title":"A controlled crossover study of triiodothyronine in autistic children","volume":"8","author":"Campbell","year":"1978","journal-title":"J Autism Child Schizophr"},{"key":"10.1016\/j.braindev.2017.03.029_b0160","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1212\/WNL.57.9.1618","article-title":"Postmortem brain abnormalities of the glutamate neurotransmitter system in autism","volume":"57","author":"Purcell","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2017.03.029_b0165","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s10803-011-1314-x","article-title":"Distinct plasma profile of polar neutral amino acids, leucine, and glutamate in children with autism spectrum disorders","volume":"42","author":"Tirouvanziam","year":"2012","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.braindev.2017.03.029_b0170","first-page":"113","article-title":"Plasma excitatory amino acids in autism","volume":"37","author":"Moreno-Fuenmayor","year":"1996","journal-title":"Invest Clin"},{"key":"10.1016\/j.braindev.2017.03.029_b0175","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1023\/A:1022238706604","article-title":"Plasma amino acid levels in children with autism and their families","volume":"33","author":"Aldred","year":"2003","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.braindev.2017.03.029_b0180","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.2174\/092986712802002572","article-title":"Glutathione-related factors and oxidative stress in autism, a review","volume":"19","author":"Ghanizadeh","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.braindev.2017.03.029_b0185","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1179\/1351000211Y.0000000012","article-title":"Urinary oxidative stress markers in children with autism","volume":"16","author":"Damodaran","year":"2011","journal-title":"Redox Rep"},{"key":"10.1016\/j.braindev.2017.03.029_b0190","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1503\/jpn.100057","article-title":"N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action","volume":"36","author":"Dean","year":"2011","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.braindev.2017.03.029_b0195","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archpsyc.56.1.21","article-title":"A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia","volume":"56","author":"Goff","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.braindev.2017.03.029_b0200","first-page":"16","article-title":"Effect of nutritional supplement containing N,N-dimethylglycine (DMG) on the racing standard bred","volume":"4","author":"Livine","year":"1982","journal-title":"Equine Pract"},{"key":"10.1016\/j.braindev.2017.03.029_b0205","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.biopsych.2011.01.026","article-title":"d-Cycloserine facilitates socially reinforced learning in an animal model relevant to autism spectrum disorders","volume":"70","author":"Modi","year":"2011","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.braindev.2017.03.029_b0210","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1079\/PNS2001130","article-title":"Dietary essential fatty acids and brain function: a developmental perspective on mechanisms","volume":"61","author":"Wainwright","year":"2002","journal-title":"Proc Nutr Soc"},{"key":"10.1016\/j.braindev.2017.03.029_b0215","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1385\/MN:32:1:089","article-title":"Lipid signaling in neural plasticity, brain repair, and neuroprotection","volume":"32","author":"Bazan","year":"2005","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.braindev.2017.03.029_b0220","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.plefa.2004.03.008","article-title":"Essential fatty acids and phospholipase A2 in autistic spectrum disorders","volume":"71","author":"Bell","year":"2004","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.braindev.2017.03.029_b0225","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s11745-006-1155-0","article-title":"EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors","volume":"38","author":"Stevens","year":"2003","journal-title":"Lipids"},{"key":"10.1016\/j.braindev.2017.03.029_b0230","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.4088\/JCP.v67n1217","article-title":"Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry","volume":"67","author":"Freeman","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.braindev.2017.03.029_b0235","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1471-2431-11-111","article-title":"Effect of a vitamin\/mineral supplement on children and adults with autism","volume":"11","author":"Adams","year":"2011","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.braindev.2017.03.029_b0240","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1007\/s10803-009-0714-7","article-title":"Complementary alternative medicine for children with autism: a physician survey","volume":"39","author":"Golnik","year":"2009","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.braindev.2017.03.029_b0245","first-page":"741","article-title":"A preliminary study of the effect of pyridoxine administration in a subgroup of hyperkinetic children: a double-blind crossover comparison with methylphenidate","volume":"14","author":"Coleman","year":"1979","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.braindev.2017.03.029_b0250","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0361-9230(79)90056-X","article-title":"Ascorbate blocks amphetamine-induced turning behavior in rats with unilateral nigro-striatal lesions","volume":"4","author":"Tolbert","year":"1979","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.braindev.2017.03.029_b0255","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0006-8993(93)91557-9","article-title":"Myo-inositol reduces serotonin (5-HT2) receptor induced homologous and heterologous desensitization","volume":"631","author":"Rahman","year":"1993","journal-title":"Brain Res"},{"key":"10.1016\/j.braindev.2017.03.029_b0260","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.3390\/nu5114521","article-title":"Cobalamin deficiency: clinical picture and radiological findings","volume":"5","author":"Briani","year":"2013","journal-title":"Nutrients"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760417301134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760417301134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T19:59:50Z","timestamp":1658951990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760417301134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0387760417301134"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2017.03.029","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of dietary supplements on clinical aspects of autism spectrum disorder: A systematic review of the literature","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2017.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}